Agape ATP shares surge 12.66% intraday after shareholder meeting approves 2026 proposals including director reappointments, $300M stock authorization, and 1:5000 reverse split.

Agape ATP surged 12.66% in intraday trading, driven by the approval of all proposals at its January 30, 2026, shareholders’ meeting. These included reappointing five directors, authorizing up to $300 million in common stock for Nasdaq compliance, and a reverse stock split of up to 1:5000, with one proposal receiving 30,095,479 votes in favor. The company specializes in health products, consulting services, and four product lines (including ATP Zeta Health Program) in Malaysia, employing 16 staff.